Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
NCT04585815 · Pfizer · PHASE1/PHASE2 · terminated · last registry update 2026-01-09 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions” | Open Targets' class: business administrative | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BRAF in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-10Results posted on the registry: Boehringer Ingelheim, BI 836880 + Ezabenlimab (NCT03468426)
- 2025-11-04Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT04452877)
- 2025-10-02Results posted on the registry: Day One Biopharmaceuticals, Inc., Tovorafenib (NCT04985604)
- 2025-10-02Also stopped (terminated): Day One Biopharmaceuticals, Inc., Tovorafenib (NCT04985604)
- 2025-08-14Also stopped (terminated): Day One Biopharmaceuticals, Inc., Tovorafenib + Tovorafenib Drug: Pimasertib (NCT07121829)
- 2025-04-13Also stopped (terminated): Novartis Pharmaceuticals, LXH254 + LTT462 (NCT02974725)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision